Therefore, treatment with CD38 antibodies may exhibit anti-tumor activity by releasing T-cell suppression via inhibition of such immunosuppressive cells, and may have therapeutic potential for solid tumors beyond hematologic malignancies such as MM. This evidence concerns the gene CD38 and neoplasm.